Trilok Parekh

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

George D. Demetri, Margaret von Mehren, Robin L. Jones et al. · Journal of Clinical Oncology · 2015 · 834 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld et al. · Journal of Clinical Oncology · 2007 · 645 citations · Full text

Medicine, Oncology, Pharmacology +17

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Rastislav Bahleda, Antoîne Italiano, Cinta Hierro et al. · Clinical Cancer Research · 2019 · 244 citations · Full text

Medicine, Oncology, Pharmacology +14

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer

Andrés Poveda, Stanley B. Kaye, Robert McCormack et al. · Gynecologic Oncology · 2011 · 178 citations

Medicine, Cell Biology, Oncology +17

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Andrés Poveda, Ignace Vergote, Sergei Tjulandin et al. · Annals of Oncology · 2010 · 168 citations · Full text

Medicine, Oncology, Pharmacology +15